Praxis secured FDA agreement to convert EMBRAVE3, its registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy, into a single-arm, baseline-controlled trial. The redesign trims enrollment to 30 patients from 40, places all participants on active treatment for 24 weeks followed by an open-label extension, and centers the primary analysis on change from baseline in countable motor seizures. Patients already in screening move directly to drug. Separately, the company expects topline data from the nine-patient EMBRAVE Part A randomized segment in the first half of 2026, with EMBRAVE3 topline also targeted for 2026.
The move reflects a pragmatic alignment with regulatory latitude in ultra-rare, high-severity pediatric epilepsies. Converting away from a sham-controlled design reduces ethical friction, accelerates referral and consent, and increases the likelihood of fully accruing a genetically defined, small patient pool. It also positions Praxis to argue for an approvable pathway anchored in seizure reduction against a patient’s own baseline, potentially supported by natural history comparators. With Orphan and Rare Pediatric Disease designations in the U.S. and PRIME status in Europe, the company is threading a familiar route for targeted ASOs in monogenic neurologic disorders: concentrate on a measurable, clinically meaningful endpoint and compress timelines by avoiding a concurrent control arm that is difficult to execute.
For sites and CRO partners, the operational center of gravity shifts to the run-in and measurement architecture. A baseline-controlled primary endpoint puts statistical credibility on the line with the quality of seizure ascertainment: diary compliance, caregiver training, adjudication rules for “countable motor seizures,” and centralized review become determinative. Without a concurrent control, regression to the mean and expectation effects must be mitigated through rigorous baseline duration, predefined responder thresholds, and sensitivity analyses, potentially including external control or natural history datasets. The open-label extension is an opportunity to demonstrate durability and functional gains beyond seizure counts, but it also elevates the need for consistent long-term safety monitoring common to ASO programs and for standardized neurodevelopmental assessments.
The redesign should ease enrollment for pediatric centers by eliminating sham procedures, while concentrating resource demands on measurement fidelity and specialized administration workflows typical of ASO studies. Vendors supporting eCOA/ePRO, video-EEG capture, and centralized seizure adjudication stand to play an outsized role. For regulators, the trial becomes an explicit test of how far single-arm, baseline-controlled designs can carry a registrational case in rare epilepsies. For payers, seizure reduction alone may prove insufficient; corroborating improvements in caregiver burden, hospitalizations, or developmental milestones will likely influence adoption and value discussions.
Key watch items include the finalized EMBRAVE3 protocol specifics: baseline run-in length, endpoint hierarchy, central adjudication methods, and statistical plans for handling variability across SCN2A gain-of-function phenotypes. Safety characterization over the 24-week core and into the extension will need to be clean and consistent, given small numbers and the absence of a control arm. Praxis will also need to demonstrate CMC reliability and site readiness for procedure-intensive dosing and monitoring. If the 2026 readouts show robust, reproducible seizure reductions with supportive functional signals, the company could plausibly pursue an accelerated pathway in the U.S. with parallel EMA engagement. The risk is clear: small-N, measurement-sensitive data may struggle to meet an approvable threshold without strong external contextualization and durable outcomes. Sponsors across the rare epilepsy space should track where FDA sets the evidentiary bar for baseline-controlled seizure endpoints—and what confirmatory commitments it expects.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
